Skip to main content

Table 1 Baseline demographic and clinical characteristics of the entire study population according to AS status

From: Increased risk of non-hematological cancer in young patients with aortic stenosis: a retrospective cohort study

 

All

(n = 105,897)

No AS

(n = 98,884)

Moderate or severe AS

(n = 7013)

P value

Age

61.1 ± 17.5

60.0 ± 17.3

77.1 ± 11.4

< 0.001

Sex

   

0.883

 Males

52,655 (49.7%)

49,162 (49.7%)

3493 (49.8%)

 

 Females

53,242 (50.3%)

49,722 (50.3%)

3520 (50.2%)

 

Ethnicity

   

< 0.001

 Arabs

7314 (6.9%)

7008 (7.1%)

306 (4.4%)

 

 Jews

98,583 (93.1%)

91,876 (92.9%)

6707 (95.6%)

 

SESa

   

0.458

 Low

17,464 (16.5%)

16,291 (16.5%)

1173 (16.7%)

 

 Middle

53,310 (50.3%)

49,820 (50.4%)

3481 (49.6%)

 

 High

33,175 (31.3%)

30,936 (31.3%)

2239 (32.0%)

 

Comorbidities and risk factors

 Smoking

38,328 (36.2%)

35,833 (36.2%)

2495 (35.6%)

0.266

 Alcohol abuse

1052 (1.0%)

992 (1.0%)

60 (0.9%)

0.238

 Obesity

25,451 (24.0%)

23,171 (23.4%)

2280 (32.5%)

< 0.001

 Previous cancer

18,725 (17.7%)

16,957 (17.1%)

1768 (25.2%)

< 0.001

 Diabetes

26,830 (25.3%)

23,976 (24.2%)

2854 (40.7%)

< 0.001

 Hypertension

54,362 (51.3%)

48,681 (49.2%)

5681 (81.0%)

< 0.001

 Congestive heart failure

11,211 (10.6%)

9095 (9.2%)

2116 (30.2%)

< 0.001

 Previous myocardial infarction

20,607 (19.5%)

18,275 (18.5%)

2332 (33.3%)

< 0.001

 Ischemic heart disease

31,523 (29.8%)

27,659 (28.0%)

3864 (55.1%)

< 0.001

 Peripheral vascular disease

9756 (9.2%)

8095 (8.2%)

1661 (23.7%)

< 0.001

 Previous stroke

11,419 (10.8%)

10,060 (10.2%)

1359 (19.4%)

< 0.001

 Atrial fibrillation

13,087 (12.4%)

10,980 (11.1%)

2107 (30.0%)

< 0.001

Medications use

 Aspirin

34,982 (33.0%)

31,334 (31.7%)

3648 (52.0%)

< 0.001

 Statin

44,690 (42.2%)

40,014 (40.5%)

4676 (66.7%)

< 0.001

 Beta blockers

31,845 (30.1%)

28,248 (28.6%)

3597 (51.3%)

< 0.001

 ACE-i/ARBs

39,413 (37.2%)

35,105 (35.5%)

4308 (61.4%)

< 0.001

 Diuretics

21,975 (20.8%)

18,930 (19.1%)

3045 (43.4%)

< 0.001

Echocardiography

 LVEDD (cm)

4.60 ± 057

4.60 ± 0.56

4.60 ± 0.67

0.975

 LVESD (cm)

2.84 ± 0.64

2.84 ± 0.63

2.98 ± 0.76

< 0.001

 IVS (cm)

1.01 ± 0.23

0.99 ± 0.22

1.24 ± 0.20

< 0.001

 PW (cm)

0.94 ± 0.19

0.92 ± 0.18

1.14 ± 0.19

< 0.001

 LV MASS (gr)

156.9 ± 60.15

152.76 ± 58.00

209.22 ± 62.00

< 0.001

As severity

 Severe AS

  

4125 (58.8%)

 

 Moderate AS

  

2888 (41.2%)

 

 Aortic valve area (cm2)

  Mean ± SD

  

0.94 ± 0.28

 

  Median (IQR)

  

0.90 (0.70–1.13)

 

 Max aortic velocity (m/s)

  Mean ± SD

  

3.53 ± 0.83

 

  Median (IQR)

  

3.46 (2.93–4.09)

 

 Mean aortic gradient (mmHg)

  Mean ± SD

  

32.0 ± 17.6

 

  Median (IQR)

  

29.0 (20.0–42.0)

 
  1. ACE-i/ARBs angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, AS aortic stenosis, IVS interventricular septum, LV left ventricular, LVEDD left ventricular end diastolic diameter, LVESD left ventricular end systolic diameter, PW posterior wall, SES socioeconomic class
  2. aSES was missing in 1957 (1.8%) patients